Patents by Inventor Tadakatsu Takahashi
Tadakatsu Takahashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8129423Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.Type: GrantFiled: October 12, 2007Date of Patent: March 6, 2012Assignee: Hoffman-La Roche Inc.Inventors: Jean Ackermann, Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander V. Mayweg, Werner Neidhart, Tadakatsu Takahashi
-
Patent number: 7935688Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.Type: GrantFiled: June 9, 2006Date of Patent: May 3, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tadakatsu Takahashi, Yoshiyuki Ono, Hirotaka Kashiwagi, Tsuyoshi Haneishi, Kazuki Shimizu
-
Publication number: 20110060146Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.Type: ApplicationFiled: November 15, 2010Publication date: March 10, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: TADAKATSU TAKAHASHI, YOSHIYUKI ONO, HIROTAKA KASHIWAGI, TSUYOSHI HANEISHI, KAZUKI SHIMIZU
-
Publication number: 20100120769Abstract: The present invention relates to compounds of formula I wherein s, R1a and R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: January 20, 2010Publication date: May 13, 2010Inventors: Matthias Nettekoven, Jean-Marc ` Plancher, Olivier Roche, Tadakatsu Takahashi, Sven Taylor
-
Patent number: 7612070Abstract: There is provided a compound represented by the general formula (1): wherein Het represents an optional substituted heterocylic group A1 and A2 each independently represent —CH?, etc.; A3 represents —CH2—, etc.; R1 represents a 4-fluorophenyl group, etc.; R2 represents an alkyl group; n represents 0, 1 or 2, provided that when A1 and A2 both are —CH?, A3 represents —CH2— or —SO2—, which is an indole derivative or a mono- or diazaindole derivative that has COX-2 inhibitory activity and is useful as a pharmaceutical, such as an anti-inflammatory agent, or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.Type: GrantFiled: February 16, 2005Date of Patent: November 3, 2009Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroharu Matsuoka, Nobuaki Kato, Tadakatsu Takahashi, Noriaki Maruyama, Takenori Ishizawa, Yukio Suzuki
-
Patent number: 7553969Abstract: Substituted phenethylamine compounds of Formula (1) that function as motilin receptor antagonists: Formula (1).Type: GrantFiled: January 28, 2000Date of Patent: June 30, 2009Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroharu Matsuoka, Tsutomu Sato, Tadakatsu Takahashi, Dong Ick Kim, Kyung Yun Jung, Chan Hee Park
-
Patent number: 7544683Abstract: The present invention relates to compounds of formula I wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: June 10, 2008Date of Patent: June 9, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Delphine Gaufreteau, Matthias Nettekoven, Jean-Marc Plancher, Olivier Roche, Sebastien Schmitt, Tadakatsu Takahashi
-
Publication number: 20090137609Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.Type: ApplicationFiled: June 9, 2006Publication date: May 28, 2009Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tadakatsu Takahashi, Yoshiyuki Ono, Hirotaka Kashiwagi, Tsuyoshi Haneishi, Kazuki Shimizu
-
Patent number: 7534788Abstract: The present invention relates to compounds of formula I wherein X, A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: July 16, 2008Date of Patent: May 19, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Peter Mohr, Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Tadakatsu Takahashi, Sven Taylor
-
Publication number: 20090029976Abstract: The present invention relates to compounds of formula I wherein X, A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: July 16, 2008Publication date: January 29, 2009Inventors: Peter Mohr, Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Tadakatsu Takahashi, Sven Taylor
-
Publication number: 20090005380Abstract: The present invention relates to compounds of formula I wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: June 10, 2008Publication date: January 1, 2009Inventors: Delphine Gaufreteau, Matthias Nettekoven, Jean-Marc Plancher, Olivier Roche, Sebastien Schmitt, Tadakatsu Takahashi
-
Publication number: 20080103183Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.Type: ApplicationFiled: October 12, 2007Publication date: May 1, 2008Inventors: Jean Ackermann, Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart, Tadakatsu Takahashi
-
Publication number: 20070167436Abstract: The present invention relates to compounds of formula I wherein s, R1a and R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: January 4, 2007Publication date: July 19, 2007Inventors: Matthias Nettekoven, Jean-Marc Plancher, Olivier Roche, Tadakatsu Takahashi, Sven Taylor
-
Patent number: 7019146Abstract: The present invention provides a novel ferrocene compound; a reagent containing the compound; a high-sensitivity method of measuring a vitamin D compound using the reagent; etc. Specifically, a ferrocene compound represented by the following formula (1): is reacted with a vitamin D compound and the combined compound of these compounds is subjected to LC/ESI-MS/MS. Thus, the VD compound can be measured with higher sensitivity than in conventional techniques. The ferrocene compound of the present invention is extremely useful as a derivatization agent when a VD compound is measured by LC/ESI-MS/MS. The obtained compound wherein the ferrocene compound and the VD compound have been combined with each other, is useful as, e.g., a labeled compound, when the VD compound is measured by LC/ESI-MS/MS.Type: GrantFiled: June 27, 2003Date of Patent: March 28, 2006Assignee: Chugai Seiyaku Kabushiki KaisyaInventors: Masaki Ishigai, Naoaki Murao, Nobuo Sekiguchi, Tadakatsu Takahashi
-
Publication number: 20060025474Abstract: The present invention discloses bisphenyl compounds of the formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.Type: ApplicationFiled: March 8, 2005Publication date: February 2, 2006Inventors: David Wallace, Thomas Arrhenius, Anna Russell, Dingguo Liu, Amy Xing, Sovouthy Tith, Zheng Hou, Tadakatsu Takahashi, Yoshiyuki Ono, Hirotaka Kashiwagi, Kazuki Shimizu, Hitoshi Ikura
-
Publication number: 20050137202Abstract: There is provided a compound represented by the general formula (1): wherein Het represents an optional substituted heterocylic group A1 and A2 each independently represent —CH?, etc.; A3 represents —CH2—, etc.; R1 represents a 4-fluorophenyl group, etc.; R2 represents an alkyl group; n represents 0, 1 or 2, provided that when A1 and A2 both are —CH?, A3 represents —CH2— or —SO2—, which is an indole derivative or a mono- or diazaindole derivative that has COX-2 inhibitory activity and is useful as a pharmaceutical, such as an anti-inflammatory agent, or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.Type: ApplicationFiled: February 16, 2005Publication date: June 23, 2005Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroharu Matsuoka, Nobuaki Kato, Tadakatsu Takahashi, Noriaki Maruyama, Takenori Ishizawa, Yukio Suzuki
-
Patent number: 6875770Abstract: There is provided a compound represented by the general formula (1): wherein Het represents an optional substituted heterocylic group A1 and A2 each independently represent —CH?, etc.; A3 represents —CH2—, etc.; R1 represents a 4-fluorophenyl group, etc.; R2 represents an alkyl group; n represents 0, 1 or 2, provided that when A1 and A2 both are —CH?, A3 represents —CH2— or —SO2—, which is an indole derivative or a mono- or diazaindole derivative that has COX-2 inhibitory activity and is useful as a pharmaceutical, such as an anti-inflammatory agent, or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.Type: GrantFiled: October 1, 2003Date of Patent: April 5, 2005Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroharu Matsuoka, Nobuaki Kato, Tadakatsu Takahashi, Noriaki Maruyama, Takenori Ishizawa, Yukio Suzuki
-
Publication number: 20040067964Abstract: There is provided a compound represented by the general formula (1): 1Type: ApplicationFiled: October 1, 2003Publication date: April 8, 2004Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroharu Matsuoka, Nobuaki Kato, Tadakatsu Takahashi, Noriaki Maruyama, Takenori Ishizawa, Yukio Suzuki
-
Patent number: 6673797Abstract: There is provided a compound represented by the general formula (1): wherein Het represents an optionally substituted heterocyclic group; A1 and A2 each independently represent —CH═, etc.; A3 represents —CH2—, etc.; R1 represents a 4-fluorophenyl group, etc.; R2 represents an alkyl group; n represents 0, 1 or 2, provided that when A1 and A2 both are —CH═, A3 represents —CH2— or —SO2—, which is an indole derivative or a mono- or diazaindole derivative that has COX-2 inhibitory activity and is useful as a pharmaceutical, such as an anti-inflammatory agent, or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.Type: GrantFiled: November 27, 2000Date of Patent: January 6, 2004Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroharu Matsuoka, Nobuaki Kato, Tadakatsu Takahashi, Noriaki Maruyama, Takenori Ishizawa, Yukio Suzuki